NR 607 Midterm Exam Prep Document | 2026/2027 Edition |
200 Verified Questions - 160 Questions with Answers
NR 607 Midterm Exam 2026-160 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NR 607 (Psychopharmacology and Advanced
Practice) provides 200 verified questions and answers, meticulously aligned with the latest 2026/2027
curriculum. Designed for nursing students, it covers all major domains including neurobiology,
psychopharmacology, and advanced practice management. Each question is accompanied by rationales
to reinforce learning and ensure exam readiness. This resource is essential for achieving a top score on
the Chamberlain University midterm exam.
Key Features:
Neurobiology and Pathophysiology of Mental Health Disorders
Pharmacokinetics and Pharmacodynamics of Psychotropic Medications
Antidepressants: SSRIs, SNRIs, TCAs, MAOIs, and Atypical Agents
Antipsychotics: First-Generation (Typical) and Second-Generation (Atypical)
Mood Stabilizers: Lithium, Anticonvulsants, and Atypical Antipsychotics
Anxiolytics and Hypnotics: Benzodiazepines, Non-Benzodiazepines, and Buspirone
Stimulants and Non-Stimulants for ADHD
Medications for Substance Use Disorders: Nicotine, Alcohol, Opioids
Special Populations: Pediatric, Geriatric, Pregnancy, and Lactation
Drug Interactions, Adverse Effects, and Monitoring Parameters
Patient Education and Adherence Strategies
Evidence-Based Prescribing and Clinical Decision-Making
Legal and Ethical Considerations in Psychopharmacology
Case Studies and Clinical Scenarios
Cultural and Genetic Considerations in Pharmacotherapy
Recent Advances and Updates in Psychopharmacology
Updates for 2026:
- Updated to reflect the latest DSM-5-TR diagnostic criteria and treatment guidelines
- Incorporated 2026-2027 American Psychiatric Association (APA) practice guidelines
- Added new questions on recently FDA-approved psychotropic medications
- Enhanced rationales with evidence-based references and clinical pearls
- Revised to include telehealth and collaborative care considerations
Abstract:
This exam preparation document is a scholarly resource designed for advanced practice nursing students enrolled
in NR 607, focusing on psychopharmacology and its application in clinical practice. It comprises 200 verified
questions that systematically cover the core competencies required for the midterm examination, including
neurobiological foundations, pharmacokinetic and pharmacodynamic principles, and the clinical use of
psychotropic agents across various psychiatric disorders. The content is organized to reflect the course syllabus,
ensuring comprehensive coverage of all major topics, from antidepressants and antipsychotics to mood stabilizers
and anxiolytics. Each question is accompanied by detailed rationales that explain the correct answer and address
common misconceptions, thereby facilitating deeper understanding and retention. The document also emphasizes
safety, monitoring, and patient education, aligning with the standards of safe and effective prescribing. By
Page 1
,integrating current evidence and guidelines, this resource serves as an indispensable tool for exam success and
future clinical practice.
Keywords:
NR 607, Psychopharmacology, Midterm Exam, Chamberlain University, Advanced Practice Nursing, Psychotropic
Medications, Verified Questions
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is indicated, followed
by a comprehensive rationale explaining why it is correct and why the other options are incorrect. Rationales
include clinical implications, mechanisms of action, and relevant guidelines to enhance understanding.
Compliance Checklist:
200 verified questions aligned with the NR 607 curriculum
Answers and rationales updated to reflect 2026-2027 guidelines
Content organized by major course domains for systematic review
Includes clinical case studies to apply knowledge in practice
Suitable for self-assessment and exam preparation
Content Area Overview:
Content Area Questions Key Topics Weight
Neurobiology and 1-20 Neurotransmitters, Brain Structures, Genetic 10%
Pathophysiology Factors, Neuroendocrine
Pharmacokinetics and 21-40 Absorption, Distribution, Metabolism, 10%
Pharmacodynamics Excretion, Receptor Binding
Antidepressants 41-70 SSRIs, SNRIs, TCAs, MAOIs, Atypical 15%
Antidepressants
Antipsychotics 71-90 Typical Antipsychotics, Atypical 10%
Antipsychotics, EPS, Metabolic Side Effects
Mood Stabilizers 91-110 Lithium, Valproate, Lamotrigine, 10%
Carbamazepine
Anxiolytics and Hypnotics 111-130 Benzodiazepines, Non-Benzodiazepine 10%
Hypnotics, Buspirone, Withdrawal
Stimulants and ADHD 131-145 Methylphenidate, Amphetamines, 7.5%
Medications Non-Stimulants (Atomoxetine), Monitoring
Substance Use Disorders 146-160 Nicotine Replacement, Alcohol 7.5%
Dependence, Opioid Agonists, Antagonists
Special Populations 161-175 Pediatric, Geriatric, Pregnancy, Lactation, 7.5%
Renal/Hepatic Impairment
Clinical Management and Safety 176-200 Drug Interactions, Adverse Effects, 12.5%
Monitoring, Patient Education, Legal/Ethical
Page 2
,Q1. A 58-year-old man with type 2 diabetes, hypertension, and chronic kidney disease
(eGFR 32 mL/min) is prescribed lisinopril. Which finding warrants immediate
discontinuation?
A. Serum potassium 5.8 mEq/L
B. Serum creatinine increase of 0.3 mg/dL from baseline
C. Blood pressure 128/76 mmHg
D. Urine albumin-to-creatinine ratio 300 mg/g
Correct Answer: A. Serum potassium 5.8 mEq/L
Rationale: Hyperkalemia (K+ >5.5 mEq/L) is a serious adverse effect of ACE inhibitors,
especially in CKD. A creatinine rise up to 30% is acceptable and not an indication to stop.
BP control and albuminuria reduction are therapeutic goals.
Why Wrong:
B - A creatinine increase of 0.3 mg/dL is within acceptable limits (up to 30% from
baseline) and does not require discontinuation.
C - A BP of 128/76 mmHg is a therapeutic target, not an adverse effect.
D - Reduction of albuminuria is a desired effect of ACE inhibitors in diabetic kidney
disease.
Reference: Lehne RA. Pharmacology for Nursing Care, 12th ed. Ch. 24: ACE Inhibitors;
KDIGO 2024 Guidelines.
Q2. Which statement about the mechanism of action of GLP-1 receptor agonists is
most accurate?
A. They increase insulin secretion only when glucose is elevated, slow gastric
emptying, and promote satiety via central pathways.
B. They inhibit DPP-4 enzyme to prolong endogenous GLP-1 action.
C. They directly activate pancreatic beta-cell potassium channels.
D. They reduce hepatic glucose production by activating AMP kinase.
Correct Answer: A. They increase insulin secretion only when glucose is elevated,
slow gastric emptying, and promote satiety via central pathways.
Rationale: GLP-1 RAs are glucose-dependent insulin secretagogues, also delaying gastric
emptying and acting on CNS to reduce appetite. DPP-4 inhibitors block enzyme, not the
receptor. Sulfonylureas close K-ATP channels; metformin activates AMPK.
Why Wrong:
B - DPP-4 inhibitors do this, not GLP-1 receptor agonists.
C - Closing K-ATP channels is the mechanism of sulfonylureas.
D - AMP kinase activation is metformin's mechanism.
Reference: Lehne RA. Pharmacology for Nursing Care, 12th ed. Ch. 45: Drugs for
Diabetes Mellitus.
Page 3
, Q3. Which combination of factors most strongly predicts poor response to
benzodiazepines in generalized anxiety disorder?
A. Co-occurring major depressive disorder and prior SSRI failure
B. History of substance use disorder and concurrent opioid therapy
C. Chronic insomnia and high baseline anxiety severity
D. Genetic polymorphism in CYP2C19 and high caffeine intake
Correct Answer: B. History of substance use disorder and concurrent opioid therapy
Rationale: Benzodiazepines are less effective and higher risk in patients with SUD and
concurrent opioid use due to tolerance, dependence, and respiratory depression.
Comorbid depression and insomnia may respond to other agents but do not preclude
benefit. CYP2C19 affects metabolism, not efficacy.
Why Wrong:
A - Comorbid depression may require additional treatment but does not predict poor
response to benzodiazepines.
C - Insomnia and severity do not predict poor response; benzodiazepines can be
effective for acute anxiety.
D - CYP2C19 polymorphism affects clearance, not therapeutic response; caffeine is a
minor factor.
Reference: Stahl SM. Stahl's Essential Psychopharmacology, 5th ed. Ch. 9: Anxiolytics.
Q4. A patient with an acute asthma exacerbation has a peak expiratory flow of 45%
of personal best. Which intervention is most appropriate first-line?
A. Oral prednisone 40 mg daily for 5 days
B. Albuterol 2.5 mg nebulized every 20 minutes for 1 hour
C. Ipratropium 0.5 mg nebulized every 6 hours
D. Montelukast 10 mg orally nightly
Correct Answer: B. Albuterol 2.5 mg nebulized every 20 minutes for 1 hour
Rationale: For moderate exacerbation (PEF 40-69%), short-acting beta-agonists are
first-line, given aggressively. Systemic corticosteroids are adjunctive. Ipratropium is
added for severe exacerbations. Montelukast is for chronic control, not acute.
Why Wrong:
A - Systemic corticosteroids are adjunctive, not first-line alone.
C - Ipratropium is adjunctive, not first-line.
D - Montelukast is not for acute exacerbations.
Reference: GINA 2024 Report: Global Strategy for Asthma Management and Prevention.
Q5. Which of the following best describes the rationale for using a fixed-dose
combination of amlodipine and atorvastatin in a patient with hypertension and
dyslipidemia?
Page 4
200 Verified Questions - 160 Questions with Answers
NR 607 Midterm Exam 2026-160 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NR 607 (Psychopharmacology and Advanced
Practice) provides 200 verified questions and answers, meticulously aligned with the latest 2026/2027
curriculum. Designed for nursing students, it covers all major domains including neurobiology,
psychopharmacology, and advanced practice management. Each question is accompanied by rationales
to reinforce learning and ensure exam readiness. This resource is essential for achieving a top score on
the Chamberlain University midterm exam.
Key Features:
Neurobiology and Pathophysiology of Mental Health Disorders
Pharmacokinetics and Pharmacodynamics of Psychotropic Medications
Antidepressants: SSRIs, SNRIs, TCAs, MAOIs, and Atypical Agents
Antipsychotics: First-Generation (Typical) and Second-Generation (Atypical)
Mood Stabilizers: Lithium, Anticonvulsants, and Atypical Antipsychotics
Anxiolytics and Hypnotics: Benzodiazepines, Non-Benzodiazepines, and Buspirone
Stimulants and Non-Stimulants for ADHD
Medications for Substance Use Disorders: Nicotine, Alcohol, Opioids
Special Populations: Pediatric, Geriatric, Pregnancy, and Lactation
Drug Interactions, Adverse Effects, and Monitoring Parameters
Patient Education and Adherence Strategies
Evidence-Based Prescribing and Clinical Decision-Making
Legal and Ethical Considerations in Psychopharmacology
Case Studies and Clinical Scenarios
Cultural and Genetic Considerations in Pharmacotherapy
Recent Advances and Updates in Psychopharmacology
Updates for 2026:
- Updated to reflect the latest DSM-5-TR diagnostic criteria and treatment guidelines
- Incorporated 2026-2027 American Psychiatric Association (APA) practice guidelines
- Added new questions on recently FDA-approved psychotropic medications
- Enhanced rationales with evidence-based references and clinical pearls
- Revised to include telehealth and collaborative care considerations
Abstract:
This exam preparation document is a scholarly resource designed for advanced practice nursing students enrolled
in NR 607, focusing on psychopharmacology and its application in clinical practice. It comprises 200 verified
questions that systematically cover the core competencies required for the midterm examination, including
neurobiological foundations, pharmacokinetic and pharmacodynamic principles, and the clinical use of
psychotropic agents across various psychiatric disorders. The content is organized to reflect the course syllabus,
ensuring comprehensive coverage of all major topics, from antidepressants and antipsychotics to mood stabilizers
and anxiolytics. Each question is accompanied by detailed rationales that explain the correct answer and address
common misconceptions, thereby facilitating deeper understanding and retention. The document also emphasizes
safety, monitoring, and patient education, aligning with the standards of safe and effective prescribing. By
Page 1
,integrating current evidence and guidelines, this resource serves as an indispensable tool for exam success and
future clinical practice.
Keywords:
NR 607, Psychopharmacology, Midterm Exam, Chamberlain University, Advanced Practice Nursing, Psychotropic
Medications, Verified Questions
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is indicated, followed
by a comprehensive rationale explaining why it is correct and why the other options are incorrect. Rationales
include clinical implications, mechanisms of action, and relevant guidelines to enhance understanding.
Compliance Checklist:
200 verified questions aligned with the NR 607 curriculum
Answers and rationales updated to reflect 2026-2027 guidelines
Content organized by major course domains for systematic review
Includes clinical case studies to apply knowledge in practice
Suitable for self-assessment and exam preparation
Content Area Overview:
Content Area Questions Key Topics Weight
Neurobiology and 1-20 Neurotransmitters, Brain Structures, Genetic 10%
Pathophysiology Factors, Neuroendocrine
Pharmacokinetics and 21-40 Absorption, Distribution, Metabolism, 10%
Pharmacodynamics Excretion, Receptor Binding
Antidepressants 41-70 SSRIs, SNRIs, TCAs, MAOIs, Atypical 15%
Antidepressants
Antipsychotics 71-90 Typical Antipsychotics, Atypical 10%
Antipsychotics, EPS, Metabolic Side Effects
Mood Stabilizers 91-110 Lithium, Valproate, Lamotrigine, 10%
Carbamazepine
Anxiolytics and Hypnotics 111-130 Benzodiazepines, Non-Benzodiazepine 10%
Hypnotics, Buspirone, Withdrawal
Stimulants and ADHD 131-145 Methylphenidate, Amphetamines, 7.5%
Medications Non-Stimulants (Atomoxetine), Monitoring
Substance Use Disorders 146-160 Nicotine Replacement, Alcohol 7.5%
Dependence, Opioid Agonists, Antagonists
Special Populations 161-175 Pediatric, Geriatric, Pregnancy, Lactation, 7.5%
Renal/Hepatic Impairment
Clinical Management and Safety 176-200 Drug Interactions, Adverse Effects, 12.5%
Monitoring, Patient Education, Legal/Ethical
Page 2
,Q1. A 58-year-old man with type 2 diabetes, hypertension, and chronic kidney disease
(eGFR 32 mL/min) is prescribed lisinopril. Which finding warrants immediate
discontinuation?
A. Serum potassium 5.8 mEq/L
B. Serum creatinine increase of 0.3 mg/dL from baseline
C. Blood pressure 128/76 mmHg
D. Urine albumin-to-creatinine ratio 300 mg/g
Correct Answer: A. Serum potassium 5.8 mEq/L
Rationale: Hyperkalemia (K+ >5.5 mEq/L) is a serious adverse effect of ACE inhibitors,
especially in CKD. A creatinine rise up to 30% is acceptable and not an indication to stop.
BP control and albuminuria reduction are therapeutic goals.
Why Wrong:
B - A creatinine increase of 0.3 mg/dL is within acceptable limits (up to 30% from
baseline) and does not require discontinuation.
C - A BP of 128/76 mmHg is a therapeutic target, not an adverse effect.
D - Reduction of albuminuria is a desired effect of ACE inhibitors in diabetic kidney
disease.
Reference: Lehne RA. Pharmacology for Nursing Care, 12th ed. Ch. 24: ACE Inhibitors;
KDIGO 2024 Guidelines.
Q2. Which statement about the mechanism of action of GLP-1 receptor agonists is
most accurate?
A. They increase insulin secretion only when glucose is elevated, slow gastric
emptying, and promote satiety via central pathways.
B. They inhibit DPP-4 enzyme to prolong endogenous GLP-1 action.
C. They directly activate pancreatic beta-cell potassium channels.
D. They reduce hepatic glucose production by activating AMP kinase.
Correct Answer: A. They increase insulin secretion only when glucose is elevated,
slow gastric emptying, and promote satiety via central pathways.
Rationale: GLP-1 RAs are glucose-dependent insulin secretagogues, also delaying gastric
emptying and acting on CNS to reduce appetite. DPP-4 inhibitors block enzyme, not the
receptor. Sulfonylureas close K-ATP channels; metformin activates AMPK.
Why Wrong:
B - DPP-4 inhibitors do this, not GLP-1 receptor agonists.
C - Closing K-ATP channels is the mechanism of sulfonylureas.
D - AMP kinase activation is metformin's mechanism.
Reference: Lehne RA. Pharmacology for Nursing Care, 12th ed. Ch. 45: Drugs for
Diabetes Mellitus.
Page 3
, Q3. Which combination of factors most strongly predicts poor response to
benzodiazepines in generalized anxiety disorder?
A. Co-occurring major depressive disorder and prior SSRI failure
B. History of substance use disorder and concurrent opioid therapy
C. Chronic insomnia and high baseline anxiety severity
D. Genetic polymorphism in CYP2C19 and high caffeine intake
Correct Answer: B. History of substance use disorder and concurrent opioid therapy
Rationale: Benzodiazepines are less effective and higher risk in patients with SUD and
concurrent opioid use due to tolerance, dependence, and respiratory depression.
Comorbid depression and insomnia may respond to other agents but do not preclude
benefit. CYP2C19 affects metabolism, not efficacy.
Why Wrong:
A - Comorbid depression may require additional treatment but does not predict poor
response to benzodiazepines.
C - Insomnia and severity do not predict poor response; benzodiazepines can be
effective for acute anxiety.
D - CYP2C19 polymorphism affects clearance, not therapeutic response; caffeine is a
minor factor.
Reference: Stahl SM. Stahl's Essential Psychopharmacology, 5th ed. Ch. 9: Anxiolytics.
Q4. A patient with an acute asthma exacerbation has a peak expiratory flow of 45%
of personal best. Which intervention is most appropriate first-line?
A. Oral prednisone 40 mg daily for 5 days
B. Albuterol 2.5 mg nebulized every 20 minutes for 1 hour
C. Ipratropium 0.5 mg nebulized every 6 hours
D. Montelukast 10 mg orally nightly
Correct Answer: B. Albuterol 2.5 mg nebulized every 20 minutes for 1 hour
Rationale: For moderate exacerbation (PEF 40-69%), short-acting beta-agonists are
first-line, given aggressively. Systemic corticosteroids are adjunctive. Ipratropium is
added for severe exacerbations. Montelukast is for chronic control, not acute.
Why Wrong:
A - Systemic corticosteroids are adjunctive, not first-line alone.
C - Ipratropium is adjunctive, not first-line.
D - Montelukast is not for acute exacerbations.
Reference: GINA 2024 Report: Global Strategy for Asthma Management and Prevention.
Q5. Which of the following best describes the rationale for using a fixed-dose
combination of amlodipine and atorvastatin in a patient with hypertension and
dyslipidemia?
Page 4
